Nesiritide
Aliases: Natrecor
Last verified: 2026-09-23
The short version
Recombinant BNP (B-type natriuretic peptide, 32 aa) — formerly approved for acute decompensated heart failure; abandoned after ASCEND-HF (no benefit). Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. ASCEND-HF 2011: neutral; US production ceased 2018. Status: discontinued. No longer available in most markets.
Identity & type
- Molecular type
- peptide
- Origin
- Recombinant BNP (B-type natriuretic peptide, 32 aa) — formerly approved for acute decompensated heart failure; abandoned after ASCEND-HF (no benefit).
Mechanism of action
NPR-A agonism → vasodilation, natriuresis, RAAS suppression.
not confirmed in humans
Dosing & routes
Official / clinical context
Development was abandoned; no active regulatory document exists. There are no official indications.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
IV bolus + infusion (historical). Natrecor: withdrawn from the market — used for acute heart decompensation; effects were modest relative to expectations.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Natrecor: withdrawn from the market — used for acute heart decompensation; effects were modest relative to expectations.
Protocol — official vs community
Official / label
Formerly approved (Natrecor, acute decompensated heart failure): 2 mcg/kg IV bolus, then 0.01 mcg/kg/min continuous infusion. The product is discontinued — this is a historical protocol, not a current one.
Duration: Continuous infusion for the acute episode; not a chronic therapy.
ASCEND-HF (2011) showed no mortality or renal benefit over standard care, settling the controversy the drug carried since its accelerated approval. US production ceased in 2018.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. ASCEND-HF 2011: neutral; US production ceased 2018.
Preclinical evidence
ASCEND-HF 2011: neutral; US production ceased 2018.
Known risks
- Hypotension, renal dysfunction (controversy).characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.